HIGHLIGHTS
- who: Caruso Teresita from the Clinical Immunology and Allergy Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, , Pisa, Italy Oncology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy have published the research: Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies, in the Journal: (JOURNAL)
- what: All the studies show that an increase in frequency of antibody production and a higher titer of antibodies is achieved with the second dose of vaccine, and recent data indicate a further increase with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.